MoviPrep (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid for Oral Solution)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
- Cardiovascular: Tachycardia, palpitations, hypertension, arrhythmia, atrial fibrillation, peripheral edema.
- Nervous system: Syncope, tremor, seizure.
- Renal: Renal impairment and/or failure.
17 PATIENT COUNSELING INFORMATION
- changes to the administration instructions (see PI for details)